Recent News

• 12.09.2025 - Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
• 12.04.2025 - Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
• 12.02.2025 - Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
• 12.01.2025 - Alpha Tau to Participate in December Investor Conferences
• 11.25.2025 - Interview with Dr. Philip Blumenfeld, Director of Advanced Radiotherapy Unit, Sharett Institute of Oncology, Hadassah Medical Center.
• 11.20.2025 - Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update
• 11.19.2025 - Interview with Dr. Mark D'Andrea - Understandind Pancreatic Cancer
• 11.11.2025 - Alpha Tau to Participate at Jefferies Global Healthcare Conference in London
• 11.02.2025 - Interview with Dr. Harold Jacob on Alpha DaRT for Pancreatic Cancer
• 10.21.2025 - Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Recent Filings

• 12.04.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.04.2025 - EX-99.1 EX-99.1
• 12.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.02.2025 - EX-99.1 EX-99.1
• 12.01.2025 - 144 Report of proposed sale of securities
• 11.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.20.2025 - EX-99.1 EX-99.1
• 11.03.2025 - 144 Report of proposed sale of securities
• 10.21.2025 - EX-99.1 EX-99.1
• 10.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]